An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

TE, Witzig; JM, Vose; PL, Zinzani; CB, Reeder; R, Buckstein; JA, Polikoff; R, Bouabdallah; C, Haioun; H, Tilly; P, Guo; D, Pietronigro; AL, Ervin-Haynes; MS, Czuczman

doi:10.1093/annonc/mdq626

Public

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

Shared by NobleBlocks on Jan 12, 2011 • 12:00 AM UTC

Authors:

Witzig TE

Vose JM

Zinzani PL

Abstract

Background Lenalidomide is an immunomodulatory agent with antitumor activity in B-cell malignancies. This phase II trial aimed to demonstrate the safety and efficacy of lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!